Education
About Us
Working with TipRanks
Follow Us
3SBio (HK:1530)
:1530
1530 Stock Chart & Stats
HK$23.90
-HK$0.07(-1.20%)
At close: 4:00 PM EST
HK$23.90
-HK$0.07(-1.20%)
Day’s Range― - ―
52-Week RangeHK$6.62 - HK$36.80
Previous CloseN/A
Volume7.16M
Average Volume (3M)31.12M
Market Cap
HK$59.95B
Enterprise ValueHK$49.99B
Total Cash (Recent Filing)HK$6.46B
Total Debt (Recent Filing)HK$1.87B
Price to Earnings (P/E)22.1
Beta0.90
Next Earnings
Mar 31, 2026EPS Estimate
4.08Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)0.63
Shares Outstanding2,538,005,400
10 Day Avg. Volume32,899,411
30 Day Avg. Volume31,124,824
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.91
Price to Sales (P/S)1.54
P/FCF Ratio6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$38.84Price Target Upside62.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue & Profit GrowthConsistent top-line and bottom-line growth through 2019–2024 demonstrates expanding commercial traction in biologics. Sustained revenue and profit growth supports predictable cash generation to fund R&D, manufacturing scale-up and market penetration over the next several quarters.
Strong Margin ProfileRobust gross and improving net margins, along with healthy EBIT/EBITDA margins, indicate durable cost control and pricing power in core products. Margin strength enhances the firm's ability to reinvest in pipelines and manufacturing and provides resilience against reimbursement or input-cost pressures.
Solid Balance Sheet & ROEA solid equity base combined with falling debt-to-equity and strong ROE increases financial resilience. Lower leverage improves capacity to fund clinical programs, capex, or strategic partnerships without excessive refinancing risk, preserving optionality and stability.
Bears Say
Inconsistent Free Cash FlowVolatile free cash flow driven by uneven capex and investing cash flows creates uncertainty in internal funding. That variability can force external financing, delay R&D/commercial projects, or constrain dividend/payout policies, weakening financial flexibility over the medium term.
Rising Total LiabilitiesAn uptick in total liabilities, despite a solid equity base, raises the prospect of higher interest costs or covenant pressure. Continued liability growth could limit capacity for M&A, capex or to absorb clinical setbacks, reducing strategic flexibility in coming quarters.
Revenue Concentration & Reimbursement RiskHeavy dependence on hospital distribution and reimbursement exposes revenue to policy and procurement changes. Structural shifts in reimbursement, pricing pressure or concentrated hospital buying can materially affect revenue predictability and margins, posing medium-term operational risk.
3SBio News
1530 FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was HK$6.62 and its highest was HK$36.80 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is HK$59.95B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Mar 31, 2026 which is in 36 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Aug 29, 2025. The company reported HK$0.633 earnings per share for the quarter, beating the consensus estimate of HK$0.577 by HK$0.057.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 0.95%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 4.08.
How many shares outstanding does 3SBio have?
3SBio has 2,538,005,400 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of HK$0.633 in its last earnings report, beating expectations of HK$0.577. Following the earnings report the stock price went up 5.499%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in HK:1530
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
456.34%
12-Months-Change
Fundamentals
Return on Equity
15.34%
Trailing 12-Months
Asset Growth
0.91%
Trailing 12-Months
Company Description
3SBio
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and DanaFarber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
1530 Stock 12 Month Forecast
Average Price Target
HK$38.84
▲(62.53% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---